Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 48 of 318 for:    IBRUTINIB

Pembrolizumab in Combination With Ibrutinib for Advanced, Refractory Colorectal Cancers

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03332498
Recruitment Status : Active, not recruiting
First Posted : November 6, 2017
Last Update Posted : September 13, 2019
Sponsor:
Collaborators:
Janssen Scientific Affairs, LLC
Merck Sharp & Dohme Corp.
Information provided by (Responsible Party):
H. Lee Moffitt Cancer Center and Research Institute

No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : Active, not recruiting
Estimated Primary Completion Date : February 2021
Estimated Study Completion Date : February 2022